Week in Review: Amgen to Build China Presence with Partnerships/M&A
Amgen is planning to increase its participation in the China market, using a combination of partnerships and M&A to build a presence; China Shenghuo Pharma received a proposal from its majority owner to take the company private at a price of $.15 per share; Zhejiang Shanshi Medical Device acquired the China distribution rights to Tensys Medical’s hemodynamic patient monitoring systems; OxOnc Development, a US oncology company, will conduct a Phase III trial of a Pfizer cancer drug in China and other East Asian countries; and Celgene Corp. of the US was granted China approval for Revlimid ® (lenalidomide) to treat multiple myeloma. More details…. Stock Symbols: (NSDQ: AMGN) (Pinksheets: CKUN) (NYSE: PFE) (NSDQ: CELG) Share this with colleagues: // //  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here